Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

SRR5088900

4d5e94e6-e595-589e-bf6b-465480d35f88

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
cancer_type_detailed
subtype

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • KRAS_SIGNALING_DN+0.300
  • MYOGENESIS+0.300
  • PANCREAS_BETA_CELLS+0.300
  • COAGULATION+0.200
  • ESTROGEN_RESPONSE_EARLY+0.200
  • APICAL_JUNCTION+0.100
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.100
  • ESTROGEN_RESPONSE_LATE+0.100
  • NOTCH_SIGNALING+0.100
  • P53_PATHWAY+0.100

Top 10 suppressed

  • E2F_TARGETS-0.500
  • IL6_JAK_STAT3_SIGNALING-0.500
  • MTORC1_SIGNALING-0.500
  • PROTEIN_SECRETION-0.500
  • UNFOLDED_PROTEIN_RESPONSE-0.500
  • ADIPOGENESIS-0.400
  • ALLOGRAFT_REJECTION-0.400
  • G2M_CHECKPOINT-0.400
  • INTERFERON_GAMMA_RESPONSE-0.400
  • MITOTIC_SPINDLE-0.400

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-W8-A86G-01A-21R-A36F-07
breast-umap@18
A0.901
2TCGA-KQ-A41N-01A-11R-A33J-07
bladder-landscape@3
0.896
3MNG771
mng-umap@100
0.888
4TCGA-E7-A4XJ-01A-11R-A26T-07
bladder-landscape@3
0.888
5SRR5088871
melanoma-umap@29
0.880
6ERR4976607
breast-umap@18
B0.879
7SRR650204
bladder-landscape@3
0.876
8MNG1258
mng-umap@100
0.876
9ERR4976602
breast-umap@18
C0.876
10SRR1392637
brain-umap@2
GTEX0.873

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 10 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
KRAS_SIGNALING_DN0.300Remibrutinib— uncovered
MYOGENESIS0.300Inavolisib— uncovered
PANCREAS_BETA_CELLS0.300Cobimetinib— uncovered
COAGULATION0.200Binimetinib— uncovered
ESTROGEN_RESPONSE_EARLY0.200Inavolisib— uncovered
APICAL_JUNCTION0.100Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.100Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.100Idelalisib— uncovered
NOTCH_SIGNALING0.100Inavolisib— uncovered
P53_PATHWAY0.100Idelalisib— uncovered